← All trials
NCT00000134
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 1992
- Primary completion
- Mar 1, 1995
- Completion date
- Mar 1, 1995
- First posted
- —
- Last posted
- —
- Enrollment
- 279
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Johns Hopkins UniversityLead sponsor
- New York Presbyterian HospitalCollaborator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- University of MiamiCollaborator
- National Eye Institute (NEI)Collaborator
- Johns Hopkins UniversityCollaborator
- University of WisconsinCollaborator
- New York UniversityCollaborator
- Northwestern UniversityCollaborator
- University of California, Los AngelesCollaborator
- University of California, San FranciscoCollaborator
- University of California, San DiegoCollaborator
- Cornell UniversityCollaborator
- Tulane UniversityCollaborator
- University of North Carolina at Chapel HillCollaborator
- Baylor UniversityCollaborator
- Johns Hopkins UniversityReponsible party - principal investigator
- Icahn School of Medicine at Mount SinaiCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.